Neurochemistry International
May 1, 2019
Hidetsugu Fujigaki, Akihiro Mouri, Yasuko Yamamoto et al.
Phencyclidine (PCP) is a dissociative anesthetic that induces psychotic symptoms and neurocognitive deficits in rodents similar to those observed in schizophrenia patients. PCP administration in healthy human subjects induces schizophrenia-like symptoms such as positive and negative symptoms, and a range of cognitive deficits. It has been reported that PCP, ketamine, and related drugs such as...
The International Journal of Neuropsychopharmacology
July 1, 2012
Akihiro Mouri, Takenao Koseki, Shiho Narusawa et al.
Administration of phencyclidine (PCP) is acknowledged to generate a model of psychosis in animals. With the identification of genetic susceptibility factors for schizophrenia and bipolar disorder, great efforts have been made to generate genetic animal models for major mental illnesses. As these disorders are multifactorial, comparisons among drug-induced (non-genetic) and genetic models are...
Neurochemistry International
2007
Akihiro Mouri, Yukihiro Noda, Takeshi Enomoto et al.
In humans, phencyclidine (PCP), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, the glutamatergic neuronal dysfunction hypothesis is one of the main explanatory hypotheses and PCP-treated animals have been utilized as an animal model of schizophrenia. The...
Annals of the New York Academy of Sciences
November 1, 2006
Toshitaka Nabeshima, Akihiro Mouri, Rina Murai et al.
In humans, phencyclidine (PCP), a noncompetitive N-methyl-d-aspartate (NMDA) antagonist, reproduces a schizophrenia-like psychosis such as positive/negative symptoms and cognitive deficits. PCP (10 mg/kg/day for 14 days)-treated mice exhibit the enhanced immobility in a forced swimming test as indexes of negative symptoms and impairment of latent learning in a water finding test as indexes of...